ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541)
:1541
Want to see HK:1541 full AI Analyst Report?
1541 Stock Chart & Stats
HK$6.15
HK$0.13(2.58%)
At close: 4:00 PM EST
HK$6.15
HK$0.13(2.58%)
Day’s Range― - ―
52-Week RangeHK$3.08 - HK$16.80
Previous CloseN/A
Volume6.41M
Average Volume (3M)4.65M
Market Cap
HK$2.87B
Enterprise ValueHK$791.11M
Total Cash (Recent Filing)HK$1.02B
Total Debt (Recent Filing)HK$228.12M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding420,477,300
10 Day Avg. Volume5,424,202
30 Day Avg. Volume4,650,789
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.73
Price to Sales (P/S)14.37
P/FCF Ratio-10.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.94
Revenue Forecast (FY)HK$122.00M
Bulls Say, Bears Say
Bulls Say
Pipeline & Therapeutic FocusA clear strategic focus on immuno-oncology biologics and related modalities positions the company in a large, structurally growing therapeutic area. Sustained investment in oncology R&D supports long-term product opportunity and partnership/commercial upside that can drive multi-year revenue streams if candidates advance.
Revenue Growth MomentumMeaningful, multi-year revenue ramp demonstrates growing commercial traction or successful licensing/partnering activity. Consistent top-line growth helps extend runway, validate market demand, and can underpin margin improvement over time as fixed R&D and commercialization costs scale more efficiently.
Balance Sheet CushionModerate leverage and a positive equity base provide financial flexibility relative to peers. A growing asset base and manageable debt reduce short-term solvency risk and improve the company’s ability to raise additional capital or absorb development setbacks without immediate distress, supporting multi-month operational continuity.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flows indicate the business has not yet established internal cash generation, forcing ongoing capital raises. Continued burn erodes runway, increases dilution risk for shareholders, and elevates execution risk if funding costs rise or capital markets tighten over the next several months.
Deep UnprofitabilityLarge, persistent operating losses and negative margins reflect structural unprofitability that must be addressed to achieve self-sustaining cash flows. Until operating economics improve through scale, cost control, or higher-margin products, profitability remains a multi-period challenge that constrains financial resilience and returns on capital.
Funding DependenceThe company’s combination of strong top-line growth but ongoing losses creates dependency on external financing to sustain development and commercialization. This structural reliance increases dilution and execution risk, tying long-term strategy to successful access to capital rather than self-funded expansion.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H News
1541 FAQ
What was ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s price range in the past 12 months?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H lowest stock price was HK$3.08 and its highest was HK$16.80 in the past 12 months.
What is ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s market cap?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s market cap is HK$2.87B.
When is ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s upcoming earnings report date?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s upcoming earnings report date is Sep 01, 2026 which is in 96 days.
How were ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s earnings last quarter?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H released its earnings results on Mar 25, 2026. The company reported -HK$0.17 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.17.
Is ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H overvalued?
According to Wall Street analysts ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s price is currently Overvalued.
Does ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H pay dividends?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H does not currently pay dividends.
What is ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s EPS estimate?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H have?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has 420,477,300 shares outstanding.
What happened to ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s price movement after its last earnings report?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H reported an EPS of -HK$0.17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.638%.
Which hedge fund is a major shareholder of ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H?
Currently, no hedge funds are holding shares in HK:1541
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.96%
12-Months-Change
Fundamentals
Return on Equity
-32.79%
Trailing 12-Months
Asset Growth
24.69%
Trailing 12-Months
Company Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, focuses on the development of immuno-oncology therapies. Its lead product candidate is IMM01, a clinical-stage CD47-targeted molecule for the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). It also develops IMM0306, a CD47×CD20 bispecific molecule for the treatment of R/R B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, a CD47×HER2 bispecific molecule for the treatment of HER2-positive and HER2-low expressing solid tumors; IMM2520, a CD47×PD-L1 bispecific molecule for the treatment of solid tumors; IMM47, a humanized monoclonal antibody targeting CD24 for cancer treatment; MM4701, a bispecific molecule that simultaneously targets CD47 and CD24; IMM2510, a bispecific molecule with a mAb-Trap structure targeting VEGF and PD-L1; IMM27M, a CTLA-4 antibody with enhanced ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody with enhanced ADCC activity. The company was founded in 2015 and is headquartered in Shanghai, China.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (1541) Earnings & Revenues
Technical Analysis
Ascletis Pharma, Inc.
―
Lepu Biopharma Co. Ltd. Class H
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
CStone Pharmaceuticals
―
Shandong Boan Biotechnology Company., Limited. Class H
―
Options Prices
Currently, No data available
---